TY - JOUR
T1 - Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease
T2 - A paired, cluster-randomised controlled trial
AU - EUROACTION Study Group
AU - Wood, D. A.
AU - Kotseva, K.
AU - Connolly, S.
AU - Jennings, C.
AU - Mead, A.
AU - Jones, J.
AU - Holden, A.
AU - De Bacquer, D.
AU - Collier, T.
AU - De Backer, G.
AU - Faergeman, O.
AU - Buxton, M. J.
AU - Graham, I.
AU - Howard, A.
AU - Logstrup, S.
AU - McGee, H.
AU - Mioulet, M.
AU - Smith, K.
AU - Thompson, D.
AU - Thomsen, T.
AU - Van Der Weijden, T.
AU - Bailey, T.
AU - Burton, S.
AU - Dean, A.
AU - Brockelmann, K.
AU - Monpère, C.
AU - Fioretti, P.
AU - Desideri, A.
AU - Brusaferro, S.
AU - Pajak, A.
AU - Kawecka-Jaszcz, K.
AU - Jankowski, P.
AU - Grodzicki, T.
AU - De Velasco, J.
AU - Maiques, A.
AU - Perk, J.
AU - Morrell, J.
AU - Alston, M.
AU - Charlesworth, D.
AU - Homewood, P.
AU - Pandya, K.
AU - Somaia, M.
AU - Graves, S.
AU - Leacock, W.
AU - Xenikaki, D.
AU - McLelland, A.
AU - Birrel, R.
AU - Beastall, G.
AU - Mistry, H.
AU - Dyer, M.
N1 - Funding Information:
This study was funded by AstraZeneca through the provision of an unconditional educational grant to the European Society of Cardiology. We thank Gary Frost, Barrie Margetts, Mike Nelson, and Charlie Foster for their advice on dietary and physical activity assessments.
Funding Information:
DAW and OF are paid consultants to AstraZeneca advisory boards and have received honoraria for speaking at AstraZeneca-sponsored meetings. GDB and DAW have received research grants from AstraZeneca, and GDB from Solvay. AM is a member of the advisory board of Flora. The other authors declare that they have no conflict of interest.
PY - 2008/6/14
Y1 - 2008/6/14
N2 - Background Our aim was to investigate whether a nurse-coordinated multidisciplinary, family-based preventive cardiology programme could improve standards of preventive care in routine clinical practice. Methods In a matched, cluster-randomised, controlled trial in eight European countries, six pairs of hospitals and six pairs of general practices were assigned to an intervention programme (INT) or usual care (UC) for patients with coronary heart disease or those at high risk of developing cardiovascular disease. The primary endpoints - measured at 1 year - were family-based lifestyle change; management of blood pressure, lipids, and blood glucose to target concentrations; and prescription of cardioprotective drugs. Analysis was by intention to treat. The trial is registered as ISRCTN 71715857. Findings 1589 and 1499 patients with coronary heart disease in hospitals and 1189 and 1128 at high risk were assigned to INT and UC, respectively. In patients with coronary heart disease who smoked in the month before the event, 136 (58%) in the INT and 154 (47%) in the UC groups did not smoke 1 year afterwards (diff erence in change 10.4%, 95% CI -0.3 to 21.2, p=0.06). Reduced consumption of saturated fat (196 [55%] vs 168 [40%]; 17.3%, 6.4 to 28.2, p=0.009), and increased consumption of fruit and vegetables (680 [72%] vs 349 [35%]; 37.3%, 18.1 to 56.5, p=0.004), and oily fi sh (156 [17%] vs 81 [8%]; 8.9%, 0.3 to 17.5, p=0.04) at 1 year were greatest in the INT group. High-risk individuals and partners showed changes only for fruit and vegetables (p=0.005). Blood-pressure target of less than 140/90 mm Hg was attained by both coronary (615 [65%] vs 547 [55%]; 10.4%, 0.6 to 20.2, p=0.04) and high-risk (586 [58%] vs 407 [41%]; 16.9%, 2.0 to 31.8, p=0.03) patients in the INT groups. Achievement of total cholesterol of less than 5 mmol/L did not diff er between groups, but in high-risk patients the diff erence in change from baseline to 1 year was 12.7% (2.4 to 23.0, p=0.02) in favour of INT. In the hospital group, prescriptions for statins were higher in the INT group (810 [86%] vs 794 [80%]; 6.0%, -0.5 to 11.5, p=0.04). In general practices in the intervention groups, angiotensin-converting enzyme inhibitors (297 [29%] INT vs 196 [20%] UC; 8.5%, 1.8 to 15.2, p=0.02) and statins (381 [37%] INT vs 232 [22%] UC; 14.6%, 2.5 to 26.7, p=0.03) were more frequently prescribed. Interpretation To achieve the potential for cardiovascular prevention, we need local preventive cardiology programmes adapted to individual countries, which are accessible by all hospitals and general practices caring for coronary and high-risk patients.
AB - Background Our aim was to investigate whether a nurse-coordinated multidisciplinary, family-based preventive cardiology programme could improve standards of preventive care in routine clinical practice. Methods In a matched, cluster-randomised, controlled trial in eight European countries, six pairs of hospitals and six pairs of general practices were assigned to an intervention programme (INT) or usual care (UC) for patients with coronary heart disease or those at high risk of developing cardiovascular disease. The primary endpoints - measured at 1 year - were family-based lifestyle change; management of blood pressure, lipids, and blood glucose to target concentrations; and prescription of cardioprotective drugs. Analysis was by intention to treat. The trial is registered as ISRCTN 71715857. Findings 1589 and 1499 patients with coronary heart disease in hospitals and 1189 and 1128 at high risk were assigned to INT and UC, respectively. In patients with coronary heart disease who smoked in the month before the event, 136 (58%) in the INT and 154 (47%) in the UC groups did not smoke 1 year afterwards (diff erence in change 10.4%, 95% CI -0.3 to 21.2, p=0.06). Reduced consumption of saturated fat (196 [55%] vs 168 [40%]; 17.3%, 6.4 to 28.2, p=0.009), and increased consumption of fruit and vegetables (680 [72%] vs 349 [35%]; 37.3%, 18.1 to 56.5, p=0.004), and oily fi sh (156 [17%] vs 81 [8%]; 8.9%, 0.3 to 17.5, p=0.04) at 1 year were greatest in the INT group. High-risk individuals and partners showed changes only for fruit and vegetables (p=0.005). Blood-pressure target of less than 140/90 mm Hg was attained by both coronary (615 [65%] vs 547 [55%]; 10.4%, 0.6 to 20.2, p=0.04) and high-risk (586 [58%] vs 407 [41%]; 16.9%, 2.0 to 31.8, p=0.03) patients in the INT groups. Achievement of total cholesterol of less than 5 mmol/L did not diff er between groups, but in high-risk patients the diff erence in change from baseline to 1 year was 12.7% (2.4 to 23.0, p=0.02) in favour of INT. In the hospital group, prescriptions for statins were higher in the INT group (810 [86%] vs 794 [80%]; 6.0%, -0.5 to 11.5, p=0.04). In general practices in the intervention groups, angiotensin-converting enzyme inhibitors (297 [29%] INT vs 196 [20%] UC; 8.5%, 1.8 to 15.2, p=0.02) and statins (381 [37%] INT vs 232 [22%] UC; 14.6%, 2.5 to 26.7, p=0.03) were more frequently prescribed. Interpretation To achieve the potential for cardiovascular prevention, we need local preventive cardiology programmes adapted to individual countries, which are accessible by all hospitals and general practices caring for coronary and high-risk patients.
UR - http://www.scopus.com/inward/record.url?scp=84961061763&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(08)60868-5
DO - 10.1016/S0140-6736(08)60868-5
M3 - Article
C2 - 18555911
AN - SCOPUS:84961061763
SN - 0140-6736
VL - 371
SP - 1999
EP - 2012
JO - The Lancet
JF - The Lancet
IS - 9629
ER -